Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates across various therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. The company’s proprietary drug candidates in clinical development comprise NKTR-118, a peripheral opioid antagonist that is in Phase III clinical trail for opioid-induced constipation; BAY41-6551 that has completed Phase II clinical trail to treat gram-negative pneumonias; and NKTR-181, a mu-opioid analgesic molecule, which is in Phase I clinical trail for chronic pain. Its other product candidates comprise NKTR-102, a topoisomerase I inhibitor, which is in Phase III clinical trail for the treatment of metastatic breast cancer; in Phase II clinical trail for platinum-resistant/refractory ovarian cancer and second-line metastatic colorectal cancer in patients with the KRAS gene mutation; and in combination with F-fluorouracil/leucovorin to treat metastatic colorectal cancer that is in Phase I clinical trial. The company’s preclinical products consists of NKTR-119 (Opioid/NKTR-118 combinations) for pain; NKTR-192 (orally-available mu-opioid analgesic molecule) to treat acute pain; NKTR-171 for neuropathic pain; and NKTR-140 for HIV. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. In addition, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, Baxter, Roche, Merck, Pfizer, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.